Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Evaluering av SPN-812 (Viloxazine Extended-release Capsule) hos barn i førskolealder med ADHD

2. oktober 2026 oppdatert av: Supernus Pharmaceuticals, Inc.

En fase 4, randomisert, dobbeltblind, multisenter, placebokontrollert, parallellgruppestudie av effektiviteten og sikkerheten til SPN-812 hos barn i førskolealder (4 til 5 år) med oppmerksomhetssvikt/hyperaktivitetsforstyrrelse (ADHD) )

This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.

Studieoversikt

Detaljert beskrivelse

This is a randomized, double-blind, placebo-controlled, multicenter, 2-arm (1:1), parallel-group, efficacy and safety/tolerability fixed-dose study of SPN-812 in preschool-age children (4 to 5 years old) with ADHD. Participants will be screened for eligibility for up to 4 weeks. Eligible participants will be treated with study medication for 6 weeks. The total duration of the study is up to 10 weeks.

Studietype

Intervensjonell

Registrering (Antatt)

286

Fase

  • Fase 4

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Alabama
      • Saraland, Alabama, Forente stater, 36571
    • Arkansas
      • Fayetteville, Arkansas, Forente stater, 72703
        • Tilbaketrukket
        • Preferred Research Partners-NWA, LLC
      • Little Rock, Arkansas, Forente stater, 72211
    • California
      • Anaheim, California, Forente stater, 92805
        • Rekruttering
        • Advanced Research Center (ARC), Inc.
        • Ta kontakt med:
      • Encino, California, Forente stater, 91316
        • Tilbaketrukket
        • Wake Research-Pharmacology Research Institute (WR-PRI), LLC [Encino]
      • Garden Grove, California, Forente stater, 92844
        • Avsluttet
        • National Institute of Clinical Research (PICR)
      • Imperial, California, Forente stater, 92251
        • Rekruttering
        • Sun Valley Research Center
        • Ta kontakt med:
      • Long Beach, California, Forente stater, 90807
        • Rekruttering
        • Alliance Research
        • Ta kontakt med:
      • Newport Beach, California, Forente stater, 92660
        • Tilbaketrukket
        • Wake Research-Pharmacology Research Institute (WR-PRI), LLC [Newport Beach]
    • Colorado
      • Centennial, Colorado, Forente stater, 80112
        • Rekruttering
        • IMMUNOe Research Centers
        • Ta kontakt med:
        • Ta kontakt med:
          • Telefonnummer: 303-773-9000
    • Florida
      • Clermont, Florida, Forente stater, 34711
        • Tilbaketrukket
        • Vertex Clinical Research, LLC
      • Coral Gables, Florida, Forente stater, 33134
        • Rekruttering
        • Luna Research Center
        • Ta kontakt med:
          • Telefonnummer: 305-613-7761
      • Gainesville, Florida, Forente stater, 32607
        • Avsluttet
        • Sarkis Clinical Trials
      • Jacksonville, Florida, Forente stater, 32256
        • Rekruttering
        • Clinical Neuroscience Solutions, Inc.
        • Ta kontakt med:
          • Telefonnummer: 904-281-5757
      • Lakeland, Florida, Forente stater, 33803
        • Avsluttet
        • Accel Research Sites - Lakeland CRU
      • Miami, Florida, Forente stater, 33155
      • Orange City, Florida, Forente stater, 32763
        • Rekruttering
        • Medical Research Group of Central Florida
        • Ta kontakt med:
          • Telefonnummer: 386-775-7627
      • Orlando, Florida, Forente stater, 32801
        • Rekruttering
        • Clinical Neuroscience Solutions, Inc.
        • Ta kontakt med:
      • Orlando, Florida, Forente stater, 32803
        • Rekruttering
        • APG Research LLC
        • Ta kontakt med:
        • Ta kontakt med:
          • Telefonnummer: 165 407-423-7149
      • Tamarac, Florida, Forente stater, 33321
        • Rekruttering
        • D&H Tamarac Research Center
        • Ta kontakt med:
      • Virginia Gardens, Florida, Forente stater, 33166
      • Winter Park, Florida, Forente stater, 32789
    • Georgia
      • Atlanta, Georgia, Forente stater, 30328
        • Rekruttering
        • Clinical Integrative Research Center of Atlanta
        • Ta kontakt med:
          • Telefonnummer: 678-705-7341
      • Atlanta, Georgia, Forente stater, 30318
        • Rekruttering
        • Advanced Discovery Research LLC
        • Ta kontakt med:
      • Decatur, Georgia, Forente stater, 30030
        • Rekruttering
        • CenExcel iResearch, LLC
        • Ta kontakt med:
          • Telefonnummer: 404-537-1281
      • Savannah, Georgia, Forente stater, 31405
        • Rekruttering
        • CenExel iResearch, LLC.
        • Ta kontakt med:
          • Telefonnummer: 912-744-0800
    • Indiana
      • Evansville, Indiana, Forente stater, 47715
        • Avsluttet
        • Qualmedica Research, LLC.
    • Kentucky
      • Bardstown, Kentucky, Forente stater, 40004
        • Rekruttering
        • Kentucky Pediatric/Adult Research
        • Ta kontakt med:
      • Owensboro, Kentucky, Forente stater, 42301
        • Avsluttet
        • Qualmedica Research, LLC.
    • Louisiana
      • New Orleans, Louisiana, Forente stater, 70115
        • Avsluttet
        • DelRicht Research (Touro Medical Center)
      • Prairieville, Louisiana, Forente stater, 70769
        • Rekruttering
        • DelRicht Research
        • Ta kontakt med:
    • Maryland
      • Baltimore, Maryland, Forente stater, 21205
        • Rekruttering
        • Kennedy Krieger Institute
        • Ta kontakt med:
          • Telefonnummer: 443-923-3850
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02445
    • Michigan
      • Bloomfield Hills, Michigan, Forente stater, 48302
        • Rekruttering
        • Neurobehavioral Medicine Group
        • Ta kontakt med:
    • Mississippi
      • Flowood, Mississippi, Forente stater, 39232
        • Rekruttering
        • Precise Research Centers
        • Ta kontakt med:
          • Telefonnummer: 601-420-5812
    • Nevada
      • Las Vegas, Nevada, Forente stater, 89128
        • Rekruttering
        • Clinical Research of Southern Nevada, LLC.
        • Ta kontakt med:
    • New Jersey
      • Berlin, New Jersey, Forente stater, 08009
        • Tilbaketrukket
        • Hassman Research Institute
      • Irvington, New Jersey, Forente stater, 07111
      • Neptune City, New Jersey, Forente stater, 07753
        • Rekruttering
        • Jersey Shore University Medical Center
        • Ta kontakt med:
    • New York
      • New York, New York, Forente stater, 10028
        • Tilbaketrukket
        • Icahn School of Medicine at Mount Sinai
    • North Carolina
      • Durham, North Carolina, Forente stater, 27705
        • Rekruttering
        • Duke University
        • Ta kontakt med:
          • Telefonnummer: 919-681-1100
    • Ohio
      • Cincinnati, Ohio, Forente stater, 45229
        • Rekruttering
        • Cincinnati Children's Hospital and Medical Center
        • Ta kontakt med:
      • West Chester, Ohio, Forente stater, 45069
        • Tilbaketrukket
        • CincyScience
    • Oregon
      • Gresham, Oregon, Forente stater, 97030
        • Rekruttering
        • Cyn3rgy Research
        • Ta kontakt med:
    • Pennsylvania
      • Hershey, Pennsylvania, Forente stater, 17033
        • Rekruttering
        • Penn State Health Medical Group - Psychiatry and Behavioral Health
        • Ta kontakt med:
        • Ta kontakt med:
          • Telefonnummer: 717-531-5656
    • South Carolina
      • North Charleston, South Carolina, Forente stater, 29405
      • Summerville, South Carolina, Forente stater, 29486
    • Tennessee
      • Memphis, Tennessee, Forente stater, 38119
        • Rekruttering
        • Clinical Neuroscience Solutions, Inc.
        • Ta kontakt med:
          • Telefonnummer: 901-843-1045
    • Texas
      • Bellaire, Texas, Forente stater, 77401
        • Tilbaketrukket
        • Houston Clinical Trials, LLC.
      • Dallas, Texas, Forente stater, 75230
        • Avsluttet
        • Javara
      • Plano, Texas, Forente stater, 75093
        • Rekruttering
        • AIM Trials, LLC
        • Ta kontakt med:
        • Ta kontakt med:
          • Telefonnummer: 214-856-2778
      • The Woodlands, Texas, Forente stater, 77381
        • Rekruttering
        • Family Psych of The Woodlands
        • Ta kontakt med:
    • Virginia
      • Petersburg, Virginia, Forente stater, 23805
      • Richmond, Virginia, Forente stater, 23220
        • Rekruttering
        • Virginia Commonwealth University, Virginia Treatment Center for Children
        • Ta kontakt med:
          • Telefonnummer: 804-628-8736

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

4 år til 5 år (Barn)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Is male or female 4 years 0 months of age to less than or equal to 5 years 9 months of age at Visit 1 (Screening) and considered medically healthy.
  2. Subject's parent(s) or legal guardian(s)/representative(s) is (are) willing and able to provide written informed consent before completing any study related procedures.
  3. Has a primary diagnosis of ADHD according to DSM-IV-TR criteria and confirmed with the Kiddie Schedule for Affective Disorders and Schizophrenia - Present and Lifetime Version (K-SADS-PL).
  4. Has an ADHD-RS-IV-P Total Score of ≥ 28 (males) or ≥ 24 (females) at Visit 1 (Screening) and at Visit 2 (Baseline).
  5. Has a CGI-S score of ≥ 4 (moderate or worse) at Visit 1 (Screening) and at Visit 2 (Baseline).
  6. Has undergone an adequate course of non-pharmacologic treatment or is having symptoms severe enough to warrant pharmacologic treatment without prior non-pharmacologic treatment.
  7. Is participating in a structured group activity (e.g., preschool, kindergarten, sports, Sunday school, summer camp or childcare program) at least 2 days a week during study so as to assess symptoms and impairment in a setting outside the home.
  8. Has not initiated any behavioral intervention/therapy within 30 days of Visit 1 (Screening) and does not plan to initiate any new or discontinue any ongoing behavioral intervention/therapy during the study (e.g., subject is eligible if behavioral intervention/therapy is initiated 30 or more days prior to Visit 1 [Screening] and continues with a similar duration/frequency throughout their study).
  9. Subjects who are on ADHD medication at Visit 1 (Screening), but whose ADHD symptoms are not well controlled on current ADHD medication (e.g., meets Inclusion Criterion #4), meet all other inclusion/exclusion criteria, and discontinues ADHD medication at least 7 days prior to the day of Visit 2 (Baseline) are eligible to participate.
  10. Has no current condition in the opinion of the Investigator that could confound efficacy assessments, safety assessments or increase participant risk.
  11. Has lived with the same parent(s) or legal guardian(s) or has lived under a shared living arrangement (e.g., joint legal custody) for greater than or equal to 6 months prior to Visit 1 (Screening).
  12. Has a body weight ≥5th percentile for age and sex at Visit 1 (Screening) and Visit 2 (Baseline).

Exclusion Criteria:

  1. Has a diagnosis at Screening (per K-SADS-PL) of another psychiatric disorder that is considered to be the primary diagnosis rather than ADHD or has a comorbid psychiatric disorder secondary to ADHD that, in the opinion of the investigator (after consulting medical monitor), will likely interfere with study treatment adherence and/or impact study results.
  2. Has a current diagnosis of a major neurological disorder. The eligibility of those who have seizures, a history of seizure-like events (e.g., syncope, myoclonus, severe muscle spasms), a family history of seizure disorder (immediate family, i.e., sibling, parent), and/or febrile seizures will be assessed on a case-by-case basis after consulting the medical monitor.
  3. History of Bipolar Disorder diagnosed in a first degree relative.
  4. Has global development delay or intellectual disability by medical history.
  5. Has a current diagnosis of a significant (per Investigator's evaluation and/or judgement) systemic disease.
  6. Has body mass index > 95th percentile for the subject's age and sex at Visit 1 (Screening) or Visit 2 (Baseline).
  7. Has a mean resting systolic and diastolic blood pressure* that are both >95th percentile for age sex, and height and has a mean resting pulse rate* that is >95th percentile for age and sex (males: >117 bpm; females: >122 bpm) at Visit 1 (Screening) or Visit 2 (Baseline). * Note: The mean of three measurements while seated.
  8. Has a clinically significant electrocardiogram finding(s) at Visit 1 (Screening).
  9. Is currently taking SPN-812 for ADHD, has previously taken SPN-812 for ADHD, but discontinued due to a lack of efficacy or adverse reactions, or has history of allergic reaction, hypersensitivity or intolerance to viloxazine.
  10. Has an allergy to or cannot swallow pudding and applesauce and cannot swallow intact capsule whole.
  11. Has any food allergy, intolerance, restriction or special diet that, in the opinion of the Investigator, could contraindicate the subject's participation in the study.
  12. Has received any investigational drug within the longer of 30 days or 5 half-lives prior to Visit 2 (e.g., first dose of study medication).
  13. Has a positive urine drug test at Visit 1 (Screening). A positive test for amphetamines is allowed for subjects receiving a stimulant ADHD medication at Screening. The subject will be required to discontinue the stimulant for the duration of the study, beginning at least 7 days prior to Visit 2 (Baseline).
  14. Is using of prohibited concomitant medications including known CYP1A2 substrates (e.g., theophylline, melatonin) during the Screening Period or (anticipated) for the duration of the study.
  15. Any reason that, in the opinion of the Investigator, would prevent the subject from participating in the study.
  16. Has suicidal ideation ("Yes" indicated on C-SSRS question 4 or 5) or suicidal behavior ("Yes" indicated on C-SSRS for any suicidal behavior) within 6 months prior to or the day of Visit 1 (Screening) or has attempted suicide ("Yes" indicated on C-SSRS for lifetime).

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Placebo komparator: Placebo

Placebo, qd

Placebo will be administered once daily

Eksperimentell: SPN-812

SPN-812, qd

100mg SPN-812 will be administered once daily and compared to Placebo

Andre navn:
  • SPN-812

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change from Baseline in the Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) Total Score at End of Study (Week 6)
Tidsramme: Baseline and Week 6

The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) consists of 18 items that correspond directly to the DSM-IV-TR criteria for ADHD. The scale is subdivided into two subscales: inattention ("IA", 9 items) and hyperactivity-impulsivity ("H/I", 9 items).The clinician rates the frequency and severity of each symptom on a 4-point Likert-type scale, where 0 = Never or rarely, 1 = Sometimes, 2 = Often, and 3 = Very often. The sum of the ratings of all 18 items yields the raw Total score (range: 0-54; the higher the Total score, the more severe the ADHD symptoms). Post-baseline raw Total scores are converted to a change from baseline Total score. A lower change from baseline ADHD-RS-IV-P Total Score (<0) represents a better outcome.

Baseline and Week 6

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change from Baseline in the Clinical Global Impression of Severity (CGI-S) Score at End of Study (Week 6)
Tidsramme: Baseline and Week 6

The Clinical Global Impression of Severity (CGI-S) is a single item clinician-rated assessment of the severity of subject's condition (ADHD symptoms) in relation to the clinician's total experience with patients with ADHD. The CGI-S is evaluated on a 7-point scale with 1 = Normal, not at all ill, asymptomatic, 2 = Borderline Ill, 3 = Mildly Ill, 4 = Moderately Ill, 5 = Markedly Ill, 6 = Severely Ill, and 7 = Among the most extremely ill patients (the higher the score, the more severe the overall ADHD symptoms). Post-baseline (raw) CGI-S scores are converted to a change from baseline score. A lower change from baseline CGI-S score (<0) represents a better outcome.

Baseline and Week 6
Clinical Global Impression of Change (CGI-C) Score at End of Study (Week 6)
Tidsramme: Week 6

The Clinical Global Impression of Change (CGI-C) is a single item clinician-rated assessment of how much the subject's condition (ADHD) has improved, worsened or has not changed relative to his/her baseline state prior to the beginning of treatment. The CGI-C is rated on a 7-point scale from 1 to 7, where 1 = "very much improved", 2 = "much improved", 3 = "minimally improved", 4 = "no change", 5 = "minimally worse", 6 = "much worse", and 7 = "very much worse". A CGI-C score <4 represents a better outcome.

Week 6
Change from Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) Hyperactivity/Impulsivity Subscale Score at End of Study (Week 6)
Tidsramme: Baseline and Week 6

The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) consists of 18 items that correspond directly to the DSM-IV-TR criteria for ADHD. The scale is subdivided into two subscales: inattention ("IA", 9 items) and hyperactivity-impulsivity ("H/I" 9 items).The clinician rates the frequency and severity of each symptom on a 4-point Likert-type scale, where 0 = Never or rarely, 1 = Sometimes, 2 = Often, and 3 = Very often. The sum of the nine H/I items yields the raw H/I subscale score (range: 0-27; the higher the H/I subscale score, the more severe the H/I symptoms). Post-baseline raw H/I subscale scores are converted to a change from baseline score. A lower change from baseline H/I subscale score (<0) represents a better outcome.

Baseline and Week 6
Change from Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) Inattention Subscale Score at End of Study (Week 6)
Tidsramme: Baseline and Week 6

The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) consists of 18 items that correspond directly to the DSM-IV-TR criteria for ADHD. The scale is subdivided into two subscales: inattention ("IA", 9 items) and hyperactivity-impulsivity ("H/I" 9 items).The clinician rates the frequency and severity of each symptom on a 4-point Likert-type scale, where 0 = Never or rarely, 1 = Sometimes, 2 = Often, and 3 = Very often. The sum of the nine IA items yields the raw IA subscale score (range: 0-27; the higher the IA subscale score, the more severe the IA symptoms). Post-baseline raw IA subscale scores are converted to a change from baseline score. A lower change from baseline IA subscale score (<0) represents a better outcome.

Baseline and Week 6
Clinical Global Impression of Severity (CGI-S) Responder Rate (percentage of subjects with CGI-S score of 1 or 2) at End of Study (Week 6)
Tidsramme: Baseline and Week 6

The Clinical Global Impression of Severity (CGI-S) is a single item clinician-rated assessment of the severity of subject's condition (ADHD symptoms) in relation to the clinician's total experience with patients with ADHD. The CGI-S is evaluated on a 7-point scale with 1 = Normal, not at all ill, asymptomatic, 2 = Borderline Ill, 3 = Mildly Ill, 4 = Moderately Ill, 5 = Markedly Ill, 6 = Severely Ill, and 7 = Among the most extremely ill patients. The responder rate (percent) is calculated by dividing "the number of 'responders' (m)" by "the number of subjects analyzed at the respective Visit/Week (n)" and multiplying the product by 100. Responder Rate values range from 0 to 100%. A percent >50% represents a greater number of "responders" versus "non-responders".

Baseline and Week 6
Clinical Global Impression of Change (CGI-C) Responder Rate (percentage of subjects with CGI-C score of 1 or 2) at End of Study (Week 6)
Tidsramme: Week 6

The Clinical Global Impression of Change (CGI-C) is a single item clinician-rated assessment of how much the subject's condition (ADHD) has improved, worsened or has not changed relative to his/her baseline state prior to the beginning of treatment. The CGI-C is rated on a 7-point scale from 1 to 7, where 1 = "very much improved", 2 = "much improved", 3 = "minimally improved", 4 = "no change", 5 = "minimally worse", 6 = "much worse", and 7 = "very much worse". The responder rate (percent) is calculated by dividing "the number of 'responders' (m)" by "the number of subjects analyzed at the respective Visit/Week (n)" and multiplying the product by 100. Responder Rate values range from 0 to 100%. A percent >50% represents a greater number of "responders" versus "non-responders".

Week 6
Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) Responder Rate (percentage of subjects with ≥ 50% Reduction in Change from Baseline) at End of Study (Week 6)
Tidsramme: Baseline and Week 6

The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) consists of 18 items that correspond directly to the DSM-IV-TR criteria for ADHD. The scale is subdivided into two 9 item subscales: inattention and hyperactivity-impulsivity. The clinician rates the frequency and severity of each symptom on a 4-point Likert-type scale; 0 = Never or rarely, 1 = Sometimes, 2 = Often, and 3 = Very often. Sum of 18 ratings yields the Total score (range: 0-54; higher score represents severer symptoms). Percent reduction is calculated for the ADHD-RS-IV-P score: [("Post-baseline"-"Baseline")/"Baseline"] x 100; range: 0 to 100%; a "responder" is a subject with a 50% or greater reduction in change from baseline Total score. Responder rate (percent of responders) is calculated: ["number of 'responders' (m)"/ "number of subjects analyzed" (n)] X 100; range: 0 to 100%. A Responder Rate greater than 50%, represents more "responders" versus "nonresponders".

Baseline and Week 6

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Joseph Hull, PhD, Supernus Pharmaceuticals, Inc.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

19. mars 2024

Primær fullføring (Antatt)

1. januar 2028

Studiet fullført (Antatt)

1. januar 2028

Datoer for studieregistrering

Først innsendt

26. februar 2021

Først innsendt som oppfylte QC-kriteriene

1. mars 2021

Først lagt ut (Faktiske)

4. mars 2021

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

5. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

2. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere